Company intelligence / Profile preview

BioBehavioral Diagnostics

Plymouth Meeting, Pennsylvania, United Statesprweb.com ↗

Ownership: Private
Development stage: Commercial

Overview

BioBehavioral Diagnostics developed the Quotient ADHD System, an FDA-cleared diagnostic tool that provides objective and quantitative assessment of core ADHD symptoms—hyperactivity, impulsivity, and inattention. The system enables clinicians to measure symptom severity and monitor response to medication or non-pharmacological interventions. It was commercially available in the U.S. by 2008[5]. The product was used in pediatric, neurology, and psychiatry offices across the United States before acquisition by Pearson[7].

Therapeutic areas: PsychiatryNeurology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

None specifically listed prior to acquisition; post-acquisition activities are under Pearson Clinical Assessment.

Beyond the preview

Go deeper on BioBehavioral Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioBehavioral Diagnostics.

Explore the full profile